Primary Treatment for a Patient with Pulmonary Tuberculosis and HIV Infection

Rationale for Anti-TB Treatment as Primary Intervention

• The European Union Standards for Tuberculosis Care recommends that all patients with tuberculosis, including those with HIV co-infection, who have not been previously treated should receive a standardized first-line anti-tuberculosis regimen 1
• Pulmonary tuberculosis with signs of decay in the lungs represents an immediate infectious risk and requires prompt treatment with anti-tuberculosis medications before initiating antiretroviral therapy 3

Recommended Anti-TB Regimen

• The initial phase should consist of 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol 1
• The continuation phase should consist of isoniazid and rifampicin given for 4 months 1

Special Considerations for TB-HIV Co-infection

• Anti-tuberculosis treatment should be initiated first, before antiretroviral therapy, to reduce the risk of immune reconstitution inflammatory syndrome (IRIS) and to better manage potential drug interactions and side effects 3
• For patients with advanced HIV disease, antiretroviral therapy should be initiated within 2-8 weeks after starting TB treatment, with timing based on CD4 count 3

Directly Observed Therapy (DOT)

• All TB treatment in this patient should be directly observed to ensure adherence, particularly given the patient's social history 5

Potential Drug Interactions and Management

• Rifampicin interacts with many antiretroviral medications, particularly protease inhibitors and non-nucleoside reverse transcriptase inhibitors 3
• Rifabutin may be substituted for rifampicin if the antiretroviral regimen includes protease inhibitors 2

Follow-up and Monitoring

• Regular monitoring of sputum smear and culture is essential to assess treatment response 1
• Liver function tests should be monitored regularly due to increased risk of hepatotoxicity in HIV-infected patients receiving anti-tuberculosis drugs 2

Potential Pitfalls and Caveats

• Never add a single drug to a failing regimen as this can lead to further drug resistance 6
• HIV-positive patients may have atypical presentations of TB with higher rates of extrapulmonary and disseminated disease 4
• Immune reconstitution inflammatory syndrome (IRIS) may occur after initiation of antiretroviral therapy, presenting as apparent worsening of TB symptoms 3